{
  "docId": "019de074-71be-772a-8bed-f9d5eaece76b",
  "docSlug": "e4f10758c80bf7a23f09bd201ccd4281",
  "documentTitle": "Alkermes | Investor Presentation Deck | 32 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 32,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "Includes a medical illustration of brain pathways related to wakefulness and neurotransmitters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-71be-772a-8bed-f9d5eaece76b/17",
  "deckHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b",
  "deckJsonHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b.json",
  "deckAnchorHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.35,
        "x": 0.62,
        "y": 0.25
      },
      "kind": "image",
      "text": "Brain diagram showing orexin pathways",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd826cdb-0cd5-4121-bced-c8a0e53a057b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "In narcolepsy and other sleep disorders, low orexin levels lead to inconsistent neurotransmitter release, resulting in excessive sleepiness and poor regulation of REM sleep. Narcolepsy affects ~200,000 people in U.S. and 3M people globally. 70% of people with narcolepsy have narcolepsy type 1, distinguished by: Cataplexy, a sudden muscle weakness triggered by strong emotions; Low or no orexin in the brain. Genetic and pharmacologic evidence suggests that orexin receptor agonists, especially OX2R agonists, may be useful for mechanistic therapy of narcolepsy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1d702d6-71c0-433c-afe7-7fd8593a8821",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1 Global Narcolepsy Drugs Market, Forecast 2019-2025. Allied Market Research. 2 Swick TJ. Treatment paradigms for cataplexy in narcolepsy: past, present, and future. Nat Sci Sleep. 2015;7:159-169. 3 Nagahara T. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J. Med. Chem. 2015;58:7931-7937. Figure from: Scammell, T E, and Saper, C B. Nature medicine. 2007;13:126-8",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c95758d1-7d6a-4e4a-aacb-7572051fd614",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "600012fd-ed0a-4afb-8c81-8ee823116b09",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Storytelling: audience calibration",
      "slug": "audience",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "072ab358-ee74-4996-a733-cf46cd50140c",
      "evidence": "The slide mentions 'narcolepsy affects ~200,000 people', indicating an audience calibration.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 17,
      "beatId": "9ecf8e3f-7143-43cb-927f-6c32ef513b5c",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 20,
      "from": 8,
      "beatId": "94c87527-871a-454f-af4f-75bda8022c1a",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "LYBALVI prescription growth trends, ALKS 2680 clinical development plan",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "187a0d0b-46a7-4879-95f2-d6fe134e2cb5",
      "evidence": "Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders",
      "position": 1,
      "objective": "why addressing orexin dysfunction is important",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}